Seisuke Nagase
The Cancer Institute Hospital · 26 works · 1,170 citations · h-index 12
Top works
- Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
- Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial
- Detection of unsuspected distant metastases and/or regional nodes by FDG-PET in LD-SCLC scan in apparent limited-disease small-cell lung cancer
- Histology and Smoking Status Predict Survival of Patients with Advanced Non–Small-Cell Lung Cancer: Results of West Japan Oncology Group (WJOG) Study 3906L
- Metachronous colon tumors: risk factors and rationale for the surveillance colonoscopy after initial polypectomy
- Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study
- Prospective screening for myocarditis in cancer patients treated with immune checkpoint inhibitors
- Palonosetron (PALO) versus granisetron (GRA) in the triplet regimen with dexamethasone (DEX) and aprepitant (APR) for preventing chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC) with cisplatin (CDDP): A randomized, double-blind, phase III trial.
- Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial.
- An anti-RNA polymerase III antibody-positive systemic sclerosis patient with thymic carcinoma whose digital ulcers healed during treatment with macitentan and sildenafil for pulmonary arterial hypertension
- Prognostic Factors for Survival After Recurrence in Patients With Completely Resected Lung Adenocarcinoma: Important Roles of Epidermal Growth Factor Receptor Mutation Status and the Current Staging System
- Individualized adjuvant chemotherapy for surgically resected lung cancer and the roles of biomarkers.
- Suppressive effect of low amounts of safflower and perilla oils on diethylnitrosamine‐induced hepatocarcinogenesis in male F344 rats
- Long-term results of S-1 plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer
- Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFR+ non-small-cell lung cancer
- [A case of pulmonary infection due to Mycobacterium simiae].
- Multicenter study of zoledronic acid administration in non‑small‑cell lung cancer patients with bone metastasis: Thoracic Oncology Research Group (TORG) 1017
- Randomized phase III study of nedaplatin (N) plus docetaxel (D) versus cisplatin (C) plus D for advanced or relapsed squamous cell carcinoma of the lung (SqLC): WJOG5208L.
- Retinoids and Liver Fibrosis
- Erratum to “Detection of unsuspected distant metastates and/or regional nodes by FDG-PET scan in apparent limited-disease small-cell lung cancer” [Lung Cancer 57 (2007) 328–333]